<DOC>
	<DOC>NCT00338507</DOC>
	<brief_summary>This clinical study is designed to explore dose ranging and identify methods to demonstrate the efficacy of Erdosteine in patients with stable Chronic Bronchitis associated with Chronic Obstructive Pulmonary Disease.</brief_summary>
	<brief_title>Phase 2 Study - Erdosteine in Patients With CB/COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Bronchitis, Chronic</mesh_term>
	<mesh_term>Erdosteine</mesh_term>
	<criteria>Adult patients with a clinical diagnosis of stable CB associated with COPD will be entered into this study. CB is diagnosed clinically in patients who have a documented smoking history and who have a daily productive cough for at least 3 months per year over at least 2 consecutive years in the absence of other causes of chronic cough. COPD is defined by the presence of airflow obstruction from spirometry asthma, bronchiectasis, or cystic fibrosis; active history of lung cancer, respiratory failure, or a need for longterm oxygen therapy;</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
</DOC>